The Efficacy of Calcipotriol + Acitretin Combination Therapy for Psoriasis

Rim, Jong Hyun; Park, Jeyoung; Choe, Yong Beom; Youn, Jai Il

doi:10.2165/00128071-200304070-00006

Cited by 43 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 In one study the number of patients clear or almost clear was increased from 41% to 67% by the addition of calcipotriol 36 and the number of patients with complete clearance increased in the other from 15% to 40% after 12 weeks. 37 …”

Section: Acitretin and Calcipotriol Ointmentmentioning

confidence: 99%

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

Ormerod

Campalani

Goodfield

2010

British Journal of Dermatology

126

154

View full text Add to dashboard Cite

Section: Acitretin and Calcipotriol Ointmentmentioning

confidence: 99%

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

Ormerod

Campalani

Goodfield

2010

British Journal of Dermatology

126

154

View full text Add to dashboard Cite

“…[109][110][111]116,117 Three trials considered the drug as a monotherapy compared with placebo 109,110 or PUVA 111 and the other two trials investigated the combination of acitretin with calcipotriol compared with acitretin alone. 116,117 There are additional trials of etretinate versus placebo; 66 however, in this review we did not assume that etretinate equated with acitretin and these trials have not been included.…”

Section: Trials Involving Acitretinmentioning

confidence: 99%

“…116, 117 One trial found that clearance was achieved significantly more often with combination therapy than with acitretin and placebo, 116 but the other trial did not. 117 Overall, the few data available indicate that acitretin has some efficacy in the treatment of psoriasis and this might be enhanced when use in combination with calcipotriol.…”

Section: Trials Involving Acitretinmentioning

confidence: 99%

See 1 more Smart Citation

Etanercept and efalizumab for the treatment of psoriasis: a systematic review

Woolacott¹,

Hawkins²,

Mason³

et al. 2006

Health Technol Assess

140

159

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

“…Its effectiveness in monotherapy is low and it is usually administered in combination with other topical or systemic treatments in order to obtain faster whitening with fewer secondary effects. It has been used in combination with vitamin D derivates applied topically (3,4) with psoralen ultraviolet A therapy (PUVA) and UVB phototherapy, and with methotrexate and cyclosporine (5).…”

Section: Sirmentioning

confidence: 99%